Losartan Potassium Tablet, Film Coated
Product Images NDC 70518-4289

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 70518-4289). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Packaging label for Losartan Potassium 100 mg oral film-coated tablets by RemedyRepack Inc. The label indicates a quantity of 30 tablets, with instructions to protect from light. It includes an NDC number 70518-4289-00, manufacturer details (Macleods Pharma, India), storage conditions, and a barcode and QR code.*

FDA Label Image

Fig.3 (Losartan Figure No 3)

A forest plot comparing hazard ratios for primary composite outcomes and stroke (fatal/non-fatal) events between Losartan potassium and Atenolol across various patient subgroups. The chart shows event rates and hazard ratios with 95% confidence intervals for groups defined by age, gender, race, ISH, diabetes, and history of cardiovascular disease in a clinical study population of 9193 patients.*

FDA Label Image

Fig.1 (Losartan Figure1)

A line graph comparing the percentage of patients with a primary endpoint over a 66-month study period for Losartan Potassium and Atenolol. The graph shows Losartan Potassium with a solid line and Atenolol with a dotted line, indicating an adjusted risk reduction of 13% (p=0.021) for Losartan Potassium.*

FDA Label Image

Fig.2 (Losartan Figure2)

A line graph comparing the percentage of patients with fatal or mortal stroke over a 60-month study period between Atenolol and Losartan Potassium. The graph shows two lines, with Losartan Potassium having a lower cumulative incidence. The chart includes an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Fig.4 (Losartan Figure4)

A line graph displaying the percentage of patients with an event over 48 months comparing Losartan Potassium and placebo. The graph shows two lines representing patients taking Losartan Potassium and those on placebo, with a risk reduction of 16.1% and a p-value of 0.022 noted on the plot.*

FDA Label Image

Str (Losartan Structure)

Chemical structure of losartan potassium showing the molecular arrangement including a tetrazole ring, a biphenyl group, and a potassium ion. The structure highlights key functional groups and bonds specific to losartan potassium.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.